TSE:4886Pharmaceuticals
ASKA Pharmaceutical Holdings (TSE:4886) Margin Slippage Reinforces Earnings Quality Concerns After Q3 Results
ASKA Pharmaceutical HoldingsLtd (TSE:4886) has put up a solid Q3 2026 print, with revenue at ¥19.2 billion and basic EPS of ¥59.09, anchored by net income of ¥1,678 million for the quarter. Over the recent quarters, the company has seen revenue move from ¥17.6 billion in Q3 2025 to ¥19.2 billion in Q3 2026, while basic EPS shifted from ¥54.23 to ¥59.09 as net income went from ¥1,538 million to ¥1,678 million. This sets a clear context for how the latest numbers fit into its recent track...